DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin

Oncogene

Volumn 31, Issue 41, 2012, Pages 4472-4483

  Mitra, A ^a   Menezes, M E ^a   Pannell, L K ^a   Mulekar, M S ^a   Honkanen, R E ^a   Shevde, L A ^a   Samant, R S ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

cancer; DNAJB6; GSK3b; OPN; PP2A; SPP1

Indexed keywords

BETA CATENIN; CHAPERONE; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 40; LYMPHOID ENHANCER FACTOR 1; OSTEOPONTIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN DNAJB6; SERINE; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INACTIVATION; FEMALE; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HSC70 HEAT-SHOCK PROTEINS; HSP40 HEAT-SHOCK PROTEINS; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MELANOMA; MICE; MICE, NUDE; MOLECULAR CHAPERONES; NEOPLASM TRANSPLANTATION; NERVE TISSUE PROTEINS; OKADAIC ACID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN PHOSPHATASE 2; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; SKIN NEOPLASMS; T CELL TRANSCRIPTION FACTOR 1; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84867399176     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.623     Document Type: Article

References (75)

1. Alonso SR, Tracey L, Ortiz P, Perez-Gomez B, Palacios J, Pollan M et al. (2007). A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67: 3450-3460. (Pubitemid 46724886)
2. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R et al. (1998). Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280: 596-599.
3. Buback F, Renkl AC, Schulz G, Weiss JM. (2009). Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Exp Dermatol 18: 750-759.
4. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V et al. (2006). The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6: 819-830. (Pubitemid 44883934)
5. Chiodoni C, Colombo MP, Sangaletti S. (2010). Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev 29: 295-307.
6. Chuang JZ, Zhou H, Zhu M, Li SH, Li XJ, Sung CH. (2002). Characterization of a brain-enriched chaperone, MRJ, that inhibits Huntingtin aggregation and toxicity independently. J Biol Chem 277: 19831-19838. (Pubitemid 34967501)
7. Clark DW, Mitra A, Fillmore RA, Jiang WG, Samant RS, Fodstad O et al. (2008). NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress. Curr Cancer Drug Targets 8: 421-430.
8. Dai YS, Xu J, Molkentin JD. (2005). The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment. Mol Cell Biol 25: 9936-9948. (Pubitemid 41572741)
9. Das S, Harris LG, Metge BJ, Liu S, Riker AI, Samant RS et al. (2009). The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J Biol Chem 284: 22888-22897.
10. Debnath J, Muthuswamy SK, Brugge JS. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268. (Pubitemid 36677560)
11. Denhardt D. (2005). Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124: xvi-xviii. (Pubitemid 40629082)
12. Dey S, Banerjee P, Saha P. (2009). Cell cycle specific expression and nucleolar localization of human J-domain containing co-chaperone Mrj. Mol Cell Biochem 322: 137-142.
13. Dhennin-Duthille I, Nyga R, Yahiaoui S, Gouilleux-Gruart V, Regnier A, Lassoued K et al. (2011). The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction. J Biol Chem 286: 5034-5042.
14. Edwards KM, Munger K. (2004). Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli. Oncogene 23: 8419-8431. (Pubitemid 39540792)
15. Eichhorn PJ, Creyghton MP, Bernards R. (2009). Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 1795: 1-15.
16. El-Tanani M, Barraclough R, Wilkinson MC, Rudland PS. (2001). Metastasis-inducing dna regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res 61: 5619-5629. (Pubitemid 32694949)
17. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. (2006). The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17: 463-474. (Pubitemid 44793123)
18. Fan CY, Lee S, Cyr DM. (2003). Mechanisms for regulation of Hsp70 function by Hsp40. Cell Stress Chaperones 8: 309-316. (Pubitemid 38222877)
19. Fernandez JJ, Candenas ML, Souto ML, Trujillo MM, Norte M. (2002). Okadaic acid, useful tool for studying cellular processes. Curr Med Chem 9: 229-262. (Pubitemid 34436443)
20. Fillmore RA, Mitra A, Xi Y, Ju J, Scammell J, Shevde LA et al. (2009). Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. Int J Cancer 125: 556-564.
21. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. (2001). The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1: 621-632. (Pubitemid 33772040)
22. Greillier L, Baas P, Welch JJ, Hasan B, Passioukov A. (2008). Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther 12: 375-390. (Pubitemid 352790451)
23. Hennessy F, Nicoll WS, Zimmermann R, Cheetham ME, Blatch GL. (2005). Not all J domains are created equal: implications for the specificity of Hsp40-Hsp70 interactions. Protein Sci 14: 1697-1709. (Pubitemid 41001413)
24. Hinoi T, Yamamoto H, Kishida M, Takada S, Kishida S, Kikuchi A. (2000). Complex formation of adenomatous polyposis coli gene product and axin facilitates glycogen synthase kinase-3 betadependent phosphorylation of beta-catenin and down-regulates beta-catenin. J Biol Chem 275: 34399-34406.
25. Howe LR, Watanabe O, Leonard J, Brown AM. (2003). Twist is upregulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 63: 1906-1913. (Pubitemid 36460857)
26. Hunter PJ, Swanson BJ, Haendel MA, Lyons GE, Cross JC. (1999). Mrj encodes a DnaJ-related co-chaperone that is essential for murine placental development. Development 126: 1247-1258. (Pubitemid 29182120)
27. Kampinga HH, Craig EA. (2010). The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol 11: 579-592.
28. Kelley WL. (1998). The J-domain family and the recruitment of chaperone power. Trends Biochem Sci 23: 222-227. (Pubitemid 28302620)
29. Kurzik-Dumke U, Czaja J. (2007). Htid-1, the human homolog of the Drosophila melanogaster l(2)tid tumor suppressor, defines a novel physiological role of APC. Cell Signal 19: 1973-1985. (Pubitemid 47081387)
30. Kurzik-Dumke U, Horner M, Czaja J, Nicotra MR, Simiantonaki N, Koslowski M et al. (2008). Progression of colorectal cancers correlates with overexpression and loss of polarization of expression of the htid-1 tumor suppressor. Int J Mol Med 21: 19-31. (Pubitemid 351222864)
31. Kushiro K, Nunez NP. (2011). Ob/ob serum promotes a mesenchymal cell phenotype in B16BL6 melanoma cells. Clin Exp Metastasis 28: 877-886.
32. Larue L, Delmas V. (2006). The WNT/Beta-catenin pathway in melanoma. Front Biosci 11: 733-742. (Pubitemid 43258176)
33. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. (2010). The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-kappaB/Snail/RKIP/PTEN circuit. Genes Cancer 1: 409-420.
34. Lopez-Bergami P, Fitchman B, Ronai Z. (2008). Understanding signaling cascades in melanoma. Photochem Photobiol 84: 289-306. (Pubitemid 351424029)
35. Lucero OM, Dawson DW, Moon RT, Chien AJ. (2010). A reevaluation of the 'oncogenic' nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep 12: 314-318.
36. Martin MJ, Carling D, Marais R. (2009). Taking the stress out of melanoma. Cancer Cell 15: 163-164.
37. Menezes ME, Devine DJ, Shevde LA, Samant RS. (2011). Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer (doi:10.1002/ijc.26449).
38. Metge BJ, Liu S, Riker AI, Fodstad O, Samant RS, Shevde LA. (2010). Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1. Oncology 78: 75-86.
39. Miller JR, Moon RT. (1996). Signal transduction through beta-catenin and specification of cell fate during embryogenesis. Genes Dev 10: 2527-2539. (Pubitemid 26357220)
40. Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J et al. (2008). Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Res 10: R22.
41. Mitra A, Menezes ME, Shevde LA, Samant RS. (2010). DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype. J Biol Chem 285: 24686-24694.
42. Mitra A, Shevde LA, Samant RS. (2009). Multi-faceted role of HSP40 in cancer. Clin Exp Metastasis 26: 559-567.
43. Moore SR, Persons DL, Sosman JA, Bobadilla D, Bedell V, Smith DD et al. (2008). Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 14: 2927-2935.
44. O'Connell MP, Weeraratna AT. (2009). Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res 22: 724-739.
45. Ohtsuka K, Hata M. (2000). Mammalian HSP40/DNAJ homologs: cloning of novel cDNAs and a proposal for their classification and nomenclature. Cell Stress Chaperones 5: 98-112.
46. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. (1997). Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 272: 24735-24738. (Pubitemid 27415637)
47. Pecina-Slaus N, Zigmund M, Kusec V, Martic TN, Cacic M, Slaus M. (2007). E-cadherin and beta-catenin expression patterns in malignant melanoma assessed by image analysis. J Cutan Pathol 34: 239-246. (Pubitemid 46239313)
48. Polanowska-Grabowska R, Simon Jr CG, Falchetto R, Shabanowitz J, Hunt DF, Gear AR. (1997). Platelet adhesion to collagen under flow causes dissociation of a phosphoprotein complex of heat-shock proteins and protein phosphatase 1. Blood 90: 1516-1526. (Pubitemid 27355423)
49. Qiu XB, Shao YM, Miao S, Wang L. (2006). The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci 63: 2560-2570. (Pubitemid 44800711)
50. Reinhold MI, Kapadia RM, Liao Z, Naski MC. (2006). The Wntinducible transcription factor Twist1 inhibits chondrogenesis. J Biol Chem 281: 1381-1388.
51. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C et al. (2008). The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1: 13.
52. Rodolfo M, Daniotti M, Vallacchi V. (2004). Genetic progression of metastatic melanoma. Cancer Lett 214: 133-147. (Pubitemid 39213938)
53. Sablina AA, Hahn WC. (2007). The role of PP2A A subunits in tumor suppression. Cell Adh Migr 1: 140-141.
54. Sablina AA, Hector M, Colpaert N, Hahn WC. (2010). Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 70: 10474-10484.
55. Saika S, Shirai K, Yamanaka O, Miyazaki K, Okada Y, Kitano A et al. (2007). Loss of osteopontin perturbs the epithelial-mesenchymal transition in an injured mouse lens epithelium. Lab Invest 87: 130-138.
56. Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. (1999). Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 283: 2089-2091.
57. Shevde LA, Das S, Clark DW, Samant RS. (2010). Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 10: 71-81.
58. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G et al. (2006). Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23: 123-133. (Pubitemid 44440172)
59. Shih Ie M, Davidson B. (2009). Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol 5: 1641-1657.
60. Tsai MF, Wang CC, Chang GC, Chen CY, Chen HY, Cheng CL et al. (2006). A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 98: 825-838.
61. Tuck AB, Chambers AF, Allan AL. (2007). Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102: 859-868. (Pubitemid 350036926)
62. Veeman MT, Slusarski DC, Kaykas A, Louie SH, Moon RT. (2003). Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol 13: 680-685. (Pubitemid 36453318)
63. Vos MJ, Hageman J, Carra S, Kampinga HH. (2008). Structural and functional diversities between members of the human HSPB, HSPH, HSPA, and DNAJ chaperone families. Biochemistry 47: 7001-7011. (Pubitemid 351956349)
64. Wai PY, Kuo PC. (2004). The role of Osteopontin in tumor metastasis. J Surg Res 121: 228-241. (Pubitemid 39387464)
65. Wang H, Brown J, Martin M. (2011). Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 53: 130-140.
66. Watson ED, Geary-Joo C, Hughes M, Cross JC. (2007). The Mrj co-chaperone mediates keratin turnover and prevents the formation of toxic inclusion bodies in trophoblast cells of the placenta. Development 134: 1809-1817. (Pubitemid 46796577)
67. Watson ED, Mattar P, Schuurmans C, Cross JC. (2009). Neural stem cell self-renewal requires the Mrj co-chaperone. Dev Dyn 238: 2564-2574.
68. Weeraratna AT. (2005). A Wnt-er wonderland-the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev 24: 237-250. (Pubitemid 40922797)
69. Whalen KA, de Jesus R, Kean JA, Schaffhausen BS. (2005). Genetic analysis of the polyomavirus DnaJ domain. J Virol 79: 9982-9990. (Pubitemid 41022339)
70. Yeatman TJ, Chambers AF. (2003). Osteopontin and colon cancer progression. Clin Exp Metastasis 20: 85-90. (Pubitemid 36308140)
71. Zhang W, Yang J, Liu Y, Chen X, Yu T, Jia J et al. (2009). PR55 alpha, a regulatory subunit of PP2A, specifically regulates PP2A-mediated beta-catenin dephosphorylation. J Biol Chem 284: 22649-22656.
72. Zhang Y, Yang Z, Cao Y, Zhang S, Li H, Huang Y et al. (2008). The Hsp40 family chaperone protein DnaJB6 enhances Schlafen1 nuclear localization which is critical for promotion of cell-cycle arrest in T-cells. Biochem J 413: 239-250.
73. Zhou BP, Hung MC. (2005). Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle 4: 772-776. (Pubitemid 41353827)
74. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI et al. (2005). Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124: 1044-1052. (Pubitemid 40629107)
75. Zuidervaart W, Pavey S, van Nieuwpoort FA, Packer L, Out C, Maat W et al. (2007). Expression of Wnt5a and its downstream effector beta-catenin in uveal melanoma. Melanoma Res 17: 380-386. (Pubitemid 350084993)